Toxicological Profile for Tetrachloroethylene

June 2019
DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.
UPDATE STATEMENT

A Toxicological Profile for Tetrachloroethylene, Draft for Public Comment was released in October 2014. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
Environmental Toxicology Branch
1600 Clifton Road NE
Mailstop S102-1
Atlanta, Georgia 30329-4027
This page is intentionally blank.
FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the most informative (i.e., key) literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention
*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA.

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to “…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.
QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances may find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance’s relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (e.g., death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section. Note that for epidemiological studies, there could be multiple routes of exposure.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

- Chapter 1: How Can (Chemical X) Affect Children?
- Chapter 1: How Can Families Reduce the Risk of Exposure to (Chemical X)?
- Section 3.7: Children’s Susceptibility
- Section 6.6: Exposures of Children

Other Sections of Interest:

- Section 3.8: Biomarkers of Exposure and Effect
- Section 3.11: Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)
Internet: http://www.atsdr.cdc.gov

The following additional materials are available online:

Case Studies in Environmental Medicine are self-instructional publications designed to increase primary health care providers’ knowledge of a hazardous substance in the environment and to aid in the evaluation of potentially exposed patients (see https://www.atsdr.cdc.gov/csem/csem.html).
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident (see https://www.atsdr.cdc.gov/MHMI/index.asp). Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFaqs™) provide answers to frequently asked questions about toxic substances (see https://www.atsdr.cdc.gov/toxfaqs/Index.asp).

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015 • Web Page: https://www.cdc.gov/nceh/.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 395 E Street, S.W., Suite 9200, Patriots Plaza Building, Washington, DC 20201 • Phone: 202-245-0625 or 1-800-CDC-INFO (800-232-4636) • Web Page: https://www.cdc.gov/niosh/.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212 • Web Page: https://www.niehs.nih.gov/.

The National Cancer Institute (NCI) is the federal government’s principal agency for cancer research and training. Contact: NCI, BG 9609 MSC 9760, 9609 Medical Center Drive, Bethesda, MD 20892-9760 • Phone: 1-800-4-CANCER (1-800-422-6237).

Clinical Resources (Publicly Available Information)

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with recognized expertise in medical toxicology. Contact: ACMT, 10645 North Tatum Boulevard, Suite 200-111, Phoenix AZ 85028 • Phone: 844-226-8333 • FAX: 844-226-8333 • Web Page: http://www.acmt.net.

The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists who respond to questions from public health professionals, clinicians, policy makers, and the public about the impact of environmental factors on the health of children and reproductive-aged adults. Contact information for regional centers can be found at http://pehsu.net/findhelp.html.

The American Association of Poison Control Centers (AAPCC) provide support on the prevention and treatment of poison exposures. Contact: AAPCC, 515 King Street, Suite 510, Alexandria VA 22314 • Phone: 701-894-1858 • Poison Help Line: 1-800-222-1222 • Web Page: http://www.aapcc.org/.
This page is intentionally blank.
CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Rae T. Benedict, Ph.D.
Nikolette Roney, M.S.
Obaid Faroon, Ph.D.
CDR Robert L. Williams, Ph.D.
Annette Ashizawa, Ph.D.
ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA

Heather Carlson-Lynch, S.M.
Julie Klotzbach, Ph.D.
Kim Zaccaria, Ph.D.
Kelly Salinas, Ph.D.
H. Danielle Johnson, B.S.
Mario Citra, Ph.D.
SRC, Inc., North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.

2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.

3. Data Needs Review. The Environmental Toxicology Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

This page is intentionally blank.
PEER REVIEW

A peer review panel was assembled for tetrachloroethylene. The panel are experts who have knowledge of tetrachloroethylene’s physical and chemical properties, toxicokinetics, key health endpoints, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended. The panel consisted of the following members:

1. Rodney R. Dietert, Ph.D., Professor of Immunotoxicology, College of Veterinary Medicine, Cornell University, Ithaca, New York;
2. Kelly G. Pennell, Ph.D., Civil and Environmental Engineering Department, University of Massachusetts-Dartmouth, North Dartmouth, Massachusetts; and
3. Jill E. Johnston, Ph.D., Department of Environmental Sciences & Engineering, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina.

In addition to the above peer reviewers, the following reviewers provided comments on the carcinogenicity discussions in the profile.

1. Neela Guha, Scientist, Ph.D., M.P.H., IARC Monographs Programme, International Agency for Research on Cancer, World Health Organization, Lyon, France
2. Aaron Blair, Ph.D., National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, Maryland

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments and ATSDR’s responses to the comments, exists as part of the administrative record for this compound. The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.
This page is intentionally blank.
# CONTENTS

---

**DISCLAIMER** .......................................................................................................................... i

**UPDATE STATEMENT** ............................................................................................................... iii

**FOREWORD** ................................................................................................................................. v

**QUICK REFERENCE FOR HEALTH CARE PROVIDERS** ........................................................... vii

**CONTRIBUTORS** ......................................................................................................................... xi

**PEER REVIEW** ............................................................................................................................... xiii

**CONTENTS** .................................................................................................................................... xv

**LIST OF FIGURES** ......................................................................................................................... xix

**LIST OF TABLES** ............................................................................................................................. xxi

---

1. **PUBLIC HEALTH STATEMENT FOR TETRACHLOROETHYLENE** ........................................ 1

2. **RELEVANCE TO PUBLIC HEALTH** ........................................................................................... 9

   2.1 **BACKGROUND AND ENVIRONMENTAL EXPOSURES TO TETRACHLOROETHYLENE** 
      IN THE UNITED STATES ........................................................................................................ 9

   2.2 **SUMMARY OF HEALTH EFFECTS** .................................................................................. 10

   2.3 **MINIMAL RISK LEVELS (MRLs)** ..................................................................................... 14

3. **HEALTH EFFECTS** .................................................................................................................... 23

   3.1 **INTRODUCTION** ............................................................................................................... 23

   3.2 **DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE** ................................. 23

   3.2.1 **Inhalation Exposure** ...................................................................................................... 24

   3.2.1.1 **Death** ...................................................................................................................... 24

   3.2.1.2 **Systemic Effects** ...................................................................................................... 26

   3.2.1.3 **Immunological and Lymphoreticular Effects** ........................................................... 71

   3.2.1.4 **Neurological Effects** ............................................................................................... 73

   3.2.1.5 **Reproductive Effects** .............................................................................................. 85

   3.2.1.6 **Developmental Effects** ........................................................................................... 89

   3.2.1.7 **Cancer** .................................................................................................................... 92

   3.2.2 **Oral Exposure** ................................................................................................................ 119

   3.2.2.1 **Death** ...................................................................................................................... 119

   3.2.2.2 **Systemic Effects** ...................................................................................................... 120

   3.2.2.3 **Immunological and Lymphoreticular Effects** ........................................................... 144

   3.2.2.4 **Neurological Effects** ............................................................................................... 146

   3.2.2.5 **Reproductive Effects** .............................................................................................. 151

   3.2.2.6 **Developmental Effects** ........................................................................................... 153

   3.2.2.7 **Cancer** .................................................................................................................... 156

   3.2.3 **Dermal Exposure** .......................................................................................................... 169

   3.2.3.1 **Death** ...................................................................................................................... 169

   3.2.3.2 **Systemic Effects** ...................................................................................................... 170

   3.2.3.3 **Immunological and Lymphoreticular Effects** ........................................................... 171

   3.2.3.4 **Neurological Effects** ............................................................................................... 171

   3.2.3.5 **Reproductive Effects** .............................................................................................. 171

   3.2.3.6 **Developmental Effects** ........................................................................................... 172

   3.2.3.7 **Cancer** .................................................................................................................... 172

   3.2.4 **Other Routes of Exposure** ............................................................................................ 172

   3.2.4.1 **Immunological and Lymphoreticular Effects** ........................................................... 172

3.3 **GENOTOXICITY** .................................................................................................................... 172

3.4 **TOXICOKINETICS** ............................................................................................................... 178
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.4.1 Absorption</td>
<td>179</td>
</tr>
<tr>
<td>3.4.1.1 Inhalation Exposure</td>
<td>179</td>
</tr>
<tr>
<td>3.4.1.2 Oral Exposure</td>
<td>184</td>
</tr>
<tr>
<td>3.4.1.3 Dermal Exposure</td>
<td>184</td>
</tr>
<tr>
<td>3.4.2 Distribution</td>
<td>186</td>
</tr>
<tr>
<td>3.4.2.1 Inhalation Exposure</td>
<td>187</td>
</tr>
<tr>
<td>3.4.2.2 Oral Exposure</td>
<td>188</td>
</tr>
<tr>
<td>3.4.2.3 Dermal Exposure</td>
<td>189</td>
</tr>
<tr>
<td>3.4.3 Metabolism</td>
<td>189</td>
</tr>
<tr>
<td>3.4.3.1 Inhalation Exposure</td>
<td>193</td>
</tr>
<tr>
<td>3.4.3.2 Oral Exposure</td>
<td>195</td>
</tr>
<tr>
<td>3.4.3.3 Dermal Exposure</td>
<td>195</td>
</tr>
<tr>
<td>3.4.4 Elimination and Excretion</td>
<td>195</td>
</tr>
<tr>
<td>3.4.4.1 Inhalation Exposure</td>
<td>195</td>
</tr>
<tr>
<td>3.4.4.2 Oral Exposure</td>
<td>198</td>
</tr>
<tr>
<td>3.4.4.3 Dermal Exposure</td>
<td>199</td>
</tr>
<tr>
<td>3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models</td>
<td>200</td>
</tr>
<tr>
<td>3.5 MECHANISMS OF ACTION</td>
<td>209</td>
</tr>
<tr>
<td>3.5.1 Pharmacokinetic Mechanisms</td>
<td>209</td>
</tr>
<tr>
<td>3.5.2 Mechanisms of Toxicity</td>
<td>210</td>
</tr>
<tr>
<td>3.5.3 Animal-to-Human Extrapolations</td>
<td>215</td>
</tr>
<tr>
<td>3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS</td>
<td>216</td>
</tr>
<tr>
<td>3.7 CHILDREN’S SUSCEPTIBILITY</td>
<td>217</td>
</tr>
<tr>
<td>3.8 BIOMARKERS OF EXPOSURE AND EFFECT</td>
<td>220</td>
</tr>
<tr>
<td>3.8.1 Biomarkers Used to Identify or Quantify Exposure to Tetrachloroethylene</td>
<td>221</td>
</tr>
<tr>
<td>3.8.2 Biomarkers Used to Characterize Effects Caused by Tetrachloroethylene</td>
<td>223</td>
</tr>
<tr>
<td>3.9 INTERACTIONS WITH OTHER CHEMICALS</td>
<td>224</td>
</tr>
<tr>
<td>3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE</td>
<td>226</td>
</tr>
<tr>
<td>3.11 METHODS FOR REDUCING TOXIC EFFECTS</td>
<td>228</td>
</tr>
<tr>
<td>3.11.1 Reducing Peak Absorption Following Exposure</td>
<td>229</td>
</tr>
<tr>
<td>3.11.2 Reducing Body Burden</td>
<td>229</td>
</tr>
<tr>
<td>3.11.3 Interfering with the Mechanism of Action for Toxic Effects</td>
<td>230</td>
</tr>
<tr>
<td>3.12 ADEQUACY OF THE DATABASE</td>
<td>230</td>
</tr>
<tr>
<td>3.12.1 Existing Information on Health Effects of Tetrachloroethylene</td>
<td>230</td>
</tr>
<tr>
<td>3.12.2 Identification of Data Needs</td>
<td>232</td>
</tr>
<tr>
<td>3.12.3 Ongoing Studies</td>
<td>251</td>
</tr>
</tbody>
</table>

4. CHEMICAL AND PHYSICAL INFORMATION                                    | 253  |
| 4.1 CHEMICAL IDENTITY                                                  | 253  |
| 4.2 PHYSICAL AND CHEMICAL PROPERTIES                                  | 253  |

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL                         | 257  |
| 5.1 PRODUCTION                                                         | 257  |
| 5.2 IMPORT/EXPORT                                                      | 258  |
| 5.3 USE                                                                | 261  |
| 5.4 DISPOSAL                                                           | 261  |

6. POTENTIAL FOR HUMAN EXPOSURE                                          | 263  |
| 6.1 OVERVIEW                                                           | 263  |
| 6.2 RELEASES TO THE ENVIRONMENT                                       | 265  |
| 6.2.1 Air                                                              | 266  |
This page is intentionally blank.
LIST OF FIGURES

3-1. Levels of Significant Exposure to Tetrachloroethylene – Inhalation ................................................ 50
3-2. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Bladder Cancer ......................................................................................... 102
3-3. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Non-Hodgkin's Lymphoma .................................................................................. 103
3-4. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Multiple Myeloma ......................................................................................... 104
3-5. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Kidney Cancer .......................................................................................... 105
3-6. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Leukemia-Lymphoma .................................................................................. 106
3-7. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Liver Cancer ............................................................................................. 107
3-8. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Pancreatic Cancer ......................................................................................... 108
3-9. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Prostate Cancer .......................................................................................... 109
3-10. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Breast Cancer .......................................................................................... 110
3-11. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Cervical Cancer .......................................................................................... 111
3-12. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Esophageal Cancer ....................................................................................... 112
3-13. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Rectal Cancer .............................................................................................. 113
3-14. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Lung Cancer .............................................................................................. 114
3-15. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Brain Cancer .............................................................................................. 115
3-16. Levels of Significant Exposure to Tetrachloroethylene – Oral ........................................................ 132
3-17. Summary of Epidemiological Studies Evaluating Associations between Oral Tetrachloroethylene and Breast Cancer .............................................................................................. 164
### LIST OF TABLES

3-1. Levels of Significant Exposure to Tetrachloroethylene – Inhalation ................................................. 27

3-2. Overview of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Cancer ......................................................................................................... 93

3-3. Hepatocellular Neoplasms in Mice Exposed to Tetrachloroethylene for 103 Weeks by Inhalation .......................................................................................................................... 117

3-4. Levels of Significant Exposure to Tetrachloroethylene – Oral ........................................................ 121

3-5. Overview of Epidemiological Studies Evaluating Associations between Oral Tetrachloroethylene and Cancer ........................................................................................................... 157

3-6. Genotoxicity of Tetrachloroethylene *In Vitro* .................................................................................. 173

3-7. Genotoxicity of Tetrachloroethylene *In Vivo* ................................................................................... 174

3-8. Partition Coefficients for Tetrachloroethylene in Mice, Rats, Dogs, and Humans .......................... 180

3-9. Metabolism of Tetrachloroethylene in Mice, Rats, and Humans ..................................................... 194

3-10. Baseline and Posterior Values of PBPK Model Parameters Selected for Optimization using MCMC ........................................................................................................................................ 205

3-11. Ongoing Studies on Tetrachloroethylene ....................................................................................... 252

4-1. Chemical Identity of Tetrachloroethylene ........................................................................................ 254

4-2. Physical and Chemical Properties of Tetrachloroethylene ................................................................ 255

5-1. Facilities that Produce, Process, or Use Tetrachloroethylene ........................................................... 259

6-1. Releases to the Environment from Facilities that Produce, Process, or Use Tetrachloroethylene ... 267

6-2. Emissions of Tetrachloroethylene .................................................................................................... 269

6-3. Tetrachloroethylene Concentrations in Ambient Air for 2006 ......................................................... 284

6-4. Percentile Distribution of Annual Mean Tetrachloroethylene Concentrations (ppb) Measured in Ambient Air at Locations Across the United States ........................................................................ 285

6-5. Geometric Mean and Selected Percentiles of Tetrachloroethylene Blood Concentrations (in ng/mL) for the U.S. Population from NHANES ........................................................................ 292

6-6. Ongoing Studies on Tetrachloroethylene ......................................................................................... 304

7-1. Analytical Methods for Determining Tetrachloroethylene in Biological Materials ....................... 307
7-2. Analytical Methods for Determining Tetrachloroethylene in Environmental Samples .................. 310

8-1. Regulations, Advisories, and Guidelines Applicable to Tetrachloroethylene ................................ 319